Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.

Abstract

BACKGROUND Complete responses are rare after medical treatment of adrenocortical tumors. We performed a single center prospective study of the antitumor effect of irinotecan (CPT-11) in patients with metastatic adrenocortical cancer. PATIENTS AND METHODS Since 1999, all patients with advanced progressive adrenocortical carcinoma, referred to the Institut… (More)

Topics

1 Figure or Table

Slides referencing similar topics